New nanoparticle therapy tested for autoimmune liver disease – first human trial complete
NCT ID NCT06798454
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This first-in-human study tested a single dose of PVT201, a nanoparticle-based drug, in 24 people: healthy volunteers and patients with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC). The main goal was to check safety and how the drug moves through the body. All patients received the drug, while some healthy volunteers got a placebo. This early research does not yet test whether the drug works, but it is a necessary step toward developing a new treatment for these autoimmune liver diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PVT201 (Navacim), a nanoparticle-based therapy designed to target immune cells involved in autoimmune disease
What this could lead to
If successful, this could pave the way for a new treatment that controls autoimmune liver diseases like PBC without lifelong medication.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, focused on safety. It is too small to prove effectiveness, and the approach is novel, so it may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX Clinical Research
Adelaide, South Australia, 5000, Australia